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Cost-effectiveness analysisa b s t r a c t
Objectives: Using dynamic transmission models we evaluated the health and cost outcomes of adding
acellular pertussis (aP) vaccination of pregnant women to infant vaccination in three Brazilian states that
represent different socioeconomic conditions. The primary objective was to determine whether the same
model structure could be used to represent pertussis disease dynamics in differing socioeconomic condi-
tions.
Methods: We tested three model structures (SIR, SIRS, SIRSIs) to represent population-level transmission
in three socio-demographically distinct Brazilian states: São Paulo, Paraná and Bahia. Two strategies were
evaluated: infant wP vaccination alone versus maternal aP immunization plus infant wP vaccination.
Model projections for 2014–2029 include outpatient and inpatient pertussis cases, pertussis deaths, years
of life lost, disability-adjusted life-years (DALYs) lost, and costs (in 2014 USD) of maternal aP vaccination,
infant vaccination, and pertussis medical treatment. Incremental cost per DALY averted is presented from
the perspective of the Brazilian National Health System.
Results: Based on goodness-of-fit statistics, the SIRSIs model fit best, although it had only a modest
improvement in statistical quantitative assessments relative to the SIRS model. For all three Brazilian
states, maternal aP immunization led to higher costs but also saved infant lives and averted DALYs.
The 2014 USD cost/DALY averted was $3068 in Sao Paulo, $2962 in Parana, and $2022 in Bahia. These
results were robust in sensitivity analyses with the incremental cost-effectiveness ratios exceeding per
capita gross regional product only when the probability that a pertussis case is reported was assumed
higher than base case implying more overt cases and deaths and therefore more medical costs.
Conclusions: The same model structure fit all three states best, supporting the idea that the disease
behaves similarly across different socioeconomic conditions. We also found that immunization of preg-
nant women with aP is cost-effective in diverse Brazilian states.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Currently, pertussis is endemic in all countries causing 16 mil-
lion cases and 195,000 child deaths annually [1], with epidemiccycles occurring every 2–5 years [2]. Childhood immunization
has led to longer intervals between pertussis outbreaks which indi-
cates increased herd immunity [3,4]. Also, a shift in the age distri-
bution of pertussis towards older age groups (adolescents and
young adults) has been reported in recent years in high-income
countries [5]. Recently, however, many countries have reported a
resurgence in pertussis cases and deaths, particularly among
infants too young to receive their own vaccinations [6,7].
P.M. Luz et al. Vaccine 39 (2021) 125–136Single-dose maternal acellular pertussis (aP) immunization
during pregnancy, which confers immunity on the infant through
transplacental antibody transfer and reduces infants’ exposure to
infection by protecting their mothers, could efficiently prevent dis-
ease and death in infants. Countries’ existing maternal immuniza-
tion programs, which already provide tetanus toxoid, offer a
feasible platform to provide maternal aP immunization, although
at additional cost. To date, economic analysis of maternal aP
immunization have shown it to be a cost-effective strategy in
high-income countries [8–10].
Brazil introduced pertussis wP vaccine into its routine child-
hood immunization program in 1973. Currently, the schedule
includes a 3 dose-primary series of pentavalent vaccine including
diphtheria, tetanus, whole-cell pertussis, Haemophilus influenzae
type b, and Hepatitis B (DTwP-Hib-HB) recommended at 2, 4 and
6 months of age, followed by two booster doses with DTwP at
15 months and 4 years of age. In the National Health System, aP
vaccines are available, free of charge, only for children at high risk
of adverse reactions to the wP vaccine (preterm infants, children
with severe neurological or cardiac conditions and those who have
previously had severe adverse events following whole-cell pertus-
sis immunization) [11]. Additionally, aP vaccines are available in
private immunization clinics. In November 2014, for pregnant
women, the Brazilian Ministry of Health replaced diphtheria-
tetanus vaccine with a single dose vaccine of tetanus-diphtheria-
acellular pertussis vaccine [12] purchased through the Pan Ameri-
can Health Organization Revolving Fund.
We tested three structures for dynamic transmission models to
explore the cost-effectiveness of maternal immunization in differ-
ent socioeconomic conditions. Because Brazil has state-specific
demographic and surveillance data we tested these model struc-
tures against data for three Brazilian states that represent a range
of socioeconomic conditions (Sao Paulo, Parana, and Bahia). These
conditions are illustrative of upper to lower-middle income set-
tings. Since many low- and middle-income countries (LMICs) do
not have enough data, of sufficient quality, to allow the develop-
ment of a country-specific dynamic transmission model, the aim
of our analysis was to determine whether a single model structure
could fit three diverse states, and thus might represent disease
dynamics in other countries with similar socioeconomic condi-
tions. Additionally, we used the models to project the health out-
comes, costs and cost-effectiveness of introducing maternal aP
immunization in these three states.2. Methods
2.1. Model structures and parameters
We developed three population-level age-structured compart-
mental models of pertussis transmission dynamics. Each model is
described by a system of differential equations with up to five
compartments to describe disease natural history and four to
describe childhood and maternal vaccination. Each of the compart-
ments is subdivided into 13 age compartments (0–1 month, 2–3,
4–5, 6–8, 9–11, 12–23 months, 2–4, 5–9, 10–14, 15–19, 20–49,
50–79, 80+ years), which were parameterized with state popula-
tion size, birth rate and age-specific death rates.
The epidemiologic models are extensions of the classic
Susceptible-Infectious-Recovered (SIR) model that includes vac-
cine compartments describing routine infant vaccination in addi-
tion to, depending on model structure, two types of infection:
primary (I) and secondary (Is). Susceptible individuals (S) of all
ages can acquire infection from contact with an infectious person126(I or Is). Time spent infected corresponds to the infectious period,
during which transmission may occur according to age-specific
force of infection. When infected individuals recover from primary
infection (I), they initially have immunity against pertussis (R) but
immunity may wane, depending on the model structure.
To identify the model structure that best fits the data for each
state, three structures with different assumptions about immunity
waning and repeat infections were tested. Our approach reflects
uncertainty surrounding the epidemiology of pertussis [13,14].
The SIR model assumes lifelong immunity and consequently no
secondary infections occur. The SIRS model assumes that immu-
nity wanes and that secondary infections are as infectious and
symptomatic (and therefore reported to the same extent) as pri-
mary infections. The SIRSI model also assumes that immunity
wanes but, compared to primary infections, secondary infections
are as infectious but less symptomatic and therefore less likely to
be reported. That is, the SIR model assumes lifelong immunity
while the SIRS and the SIRSI models assume immunity wanes
and that individuals become susceptible to repeat primary infec-
tions (model SIRS) or secondary infections (Is, model SIRSI).
Routine infant whole-cell pertussis (wP) vaccination occurs at
2–3, 4–5, 6–8, 9–11, 12–23 months depending on the observed
probability of receiving each of the primary childhood doses. These
probabilities determine the fraction of infants that moves from the
susceptible (S) or the maternal immunization (Vm, see below)
compartments to the vaccinated compartments (V1: first dose,
V2: second dose, V3: third dose). Infants vaccinated against pertus-
sis may be protected by vaccination (V1p) or not protected (V1n)
depending on the primary vaccine failure probability (vf). From
vaccine protected compartments (V1p, V2p, V3p), upon waning,
they may become susceptible to infection (move to S). Immunity
from both routine vaccination (V) and maternal immunization
(Mv) wane at different rates.
Maternal immunization is modeled by assigning a fraction of
newborns, based on vaccine coverage, into a maternally immune
compartment (Vm) which is further subdivided into a protected
(Vmp) and not protected (Vmn) depending on vaccine effective-
ness. When maternal immunity wanes, those initially protected
become susceptible to pertussis infection (S). All ‘‘not protected”
compartments are as susceptible as S. All ‘‘protected” compart-
ments are immune, with different waning immunity rates.
Force of infection was defined for each age group according to
effective contact rates and number of infected people. We modeled
the contact between age-compartments based on a contact matrix
that describes the average number of contacts per day that each
individual is likely to have with another individual. Since an
empirically-derived matrix is not yet available for Brazil, we
adapted one for a middle-income country, Poland [15], to the
Brazilian scenario by adjusting the published matrix by the ratio
of average household size (Poland::Brazil) and subsequently to
each state (Brazil::State). The Polish matrix was chosen based on
a qualitative assessment of the similarities of the contact patterns
in the two countries. For use in the model, the original matrix,
which used 5-year age groups, was condensed/expanded as neces-
sary to map to the 13 age groups in the present study. Additionally,
the matrix was corrected for reciprocity - that is, following prior
studies, it was adjusted so that the off-diagonal elements were
symmetric and the contact rate was the same for any two age-
groups regardless of which group initiated contact [16].
The model includes parameters to quantify duration and degree
of infectiousness; duration of natural, vaccine, and maternally
acquired immunity; efficacy and coverage of infant and maternal
vaccines; and the likelihood that whole-cell or acellular vaccine
will fail to protect. Parameter values, ranges and sources are
P.M. Luz et al. Vaccine 39 (2021) 125–136described in Table 1, a more thorough description is given in the
Technical Appendix, Section #8.
2.2. Data
We modeled maternal aP immunization in three states: (a) São
Paulo in Southeast Brazil, (b) Paraná in the South, and (c) Bahia in
the Northeast. São Paulo is the most populous, the most developed,
ranking 2nd in the country (out of 27) on the human development
index and has the highest per capita income (Table 2) [22]. The
gross regional product per capita (the equivalent of the gross
domestic product for the regions of a country) mirrors the previous
statistics and, in 2014, was 17,881 USD in São Paulo, 13,310 USD in
Paraná and 6273 USD in Bahia [23]. Infant vaccine coverage was
lowest in Bahia in the two nationally representative surveys
(Table 2) [24,25].
2.3. Pertussis epidemiology
In Brazil, notification of pertussis is compulsory, and the clini-
cal, epidemiologic and laboratory criteria used for case classifica-
tion are standardized and periodically revised by the nationalTable 1
Model parameters: symbol, description, sources, and base case values (range).
Symbol Description Definitions and sources
Demography
Births Births # of births/day, state da
Appendix, Section #1.
d Ageing 1/duration of age group
group i = 1–12, there is
m Mortality Mortality rate from all ca
Statistics and all-cause m
Section #1. Defined for
Natural history
fi Force of infection Time-dependent parame
any given time. Defined
ci,j Contact rate between age group i (i = 1–13)
and age group j (j = 1–13)
Polish POLYMOD matrix
Technical Appendix, Sec
pi Transmission probability per contact Initial values for each sta
Section #1. Defined for
g 1/infectious period 1/25 days (21–28). Initia
Appendix, Section #1 an
wi Waning of infection induced immunity 25 years (10–50). Derive
mpi Pertussis-specific mortality Mortality rate from pert
Statistics and pertussis-
Section #2. Defined for




model structure SIRSI, w
Vaccine coverage
vc1 Vaccine coverage wP, 1st dose Probability of being vacc
in Brazil in 2007. See Te
vc2 Vaccine coverage wP, 2nd dose Probability of being vacc
in Brazil in 2007. See Te
vc3 Vaccine coverage wP, 3rd dose Probability of being vacc
in Brazil in 2007. See Te
vcm Vaccine coverage aP, maternal State-specific data from
Vaccine effectiveness
ve1 Effectiveness wP, 1st dose 0.68 (95%CI: 0.456–0.81
ve2 Effectiveness wP, 2nd dose 0.92 (95% CI: 0.847–0.95
ve3 Effectiveness wP, 3rd dose 0.99 (95% CI: 0.989–1.00
vem Effectiveness aP, maternal 0.91 (95% CI:0.82–0.95)
Primary vaccine failure
vfw Proportion of vaccine failure, wP 0.1 (0–0.15) [21]
vfa Proportion of vaccine failure, aP 0.1 (0–0.15) [16]
Immunity waning
w1 Waning immunity of wP 1st dose 14.5 years (range 5–30 y
w2 Waning immunity of wP 2nd dose 14.5 years (range 5–30 y
w3 Waning immunity of wP 3rd dose 14.5 years (range 5–30 y
wm Waning immunity of aP, infant* 3 months (range 2–4 mo
* Waning of immunity in the infant; waning of immunity in the pregnant woman is n
Brazilian states modelled in the present analysis: São Paulo, Paraná and Bahia.
127public health surveillance system [11]. We undertook a compre-
hensive review of available demographic, epidemiologic, and mor-
tality data for the three states (see the Technical Appendix,
Section #2). Mandatory notification of pertussis cases has been in
place since 1973 (in electronic format since 1998) and notified
cases are available through the Brazilian National Notifiable
Surveillance System (SINAN) [11]. Suspected cases are defined
based on symptoms while confirmation of suspected cases can
be based on clinical, laboratory, or epidemiological criteria [11].
We considered all confirmed cases, irrespective of confirmation
criteria, and defined outpatient cases as all confirmed cases in
the surveillance information system except for those indicated as
requiring hospitalization. Hospitalized cases were obtained from
the Brazilian Hospitalization Information System (SIH, Sistema de
Informações Hospitalares do SUS) and were defined as all individ-
uals hospitalized within SUS in which the main cause of hospital-
ization was reported as being pertussis. Since these represent only
hospitalizations occurring within the public health system, we
adjusted the number of hospitalizations by public health system
(SUS) coverage in each state to estimate all hospitalizations. Deaths
from pertussis were obtained from the Brazilian Mortality Infor-
mation System (SIM, Sistema de Informação de Mortalidade).ta from the Brazilian National Institute of Geography and Statistics. See Technical
. For example, for the age group 10–14 years, duration is 5 years. Defined for age
no ageing parameter for the last age group.
uses, state-specific population data from the National Institute of Geography and
ortality data from the National Mortality System. See Technical Appendix,
age group i = 1–13.
ter based on age-specific contact rates and the pool of infectious individuals at
for age group i = 1–13.
[15] adjusted for average state-specific household size. See Methods and
tion #1.
te based on [17] and then adjusted during model fitting, see Technical Appendix,
age group i = 1–13.
l values based on [8] and then adjusted during model fitting. See Technical
d #6.
d during model fitting, see Technical Appendix, Section #1 and #6.
ussis, state-specific population data from the National Institute of Geography and
specific mortality data from National Mortality System. See Technical Appendix,
age group i = 1–5.
that an infection will be symptomatic/reported. Derived during model fitting, see
tion #1 and #6. The reporting probability for secondary infections, applicable to
as assumed to be 1/10 of that of the primary infection.
inated, estimated from the National Survey of Vaccine Coverage in State Capitals
chnical Appendix for details, Section #3.
inated, estimated from the National Survey of Vaccine Coverage in State Capitals
chnical Appendix for details, Section #3.
inated, estimated from the National Survey of Vaccine Coverage in State Capitals
chnical Appendix for details, Section #3.





ears). Derived during model fitting, see Technical Appendix, Section #1 and #6.
ears). Derived during model fitting, see Technical Appendix, Section #1 and #6.
ears). Derived during model fitting, see Technical Appendix, Section #1 and #6.
nths) [16]
ot modeled. State-specific means that data or parameters are specific to each of the
Table 2
Summary of the characteristics of the states.
Sao Paulo Parana Bahia Source
Population (millions, 2018) 45 11 15 [22]
Per capita income (monthly, Reais, 2017) 1712 1472 862 [22]
Employment (ind.  16 years of age, 2017) 72% 68% 40% [22]
Human development index (HDI, 2010) 0.783 0.749 0.660 [22]
Relative HDI ranking (out of 27) 2nd 6th 22nd [22]
Gross regional product per capita (USD) 17,881 13,310 6273 [23]
Vaccination
1991 birth cohort, assessed 1996, by region 72.9# 87.1# 60.7# [25]
2005 birth cohort, assessed 2007, by state capital 83.0* 97.7* 78.7* [24]
# Percent of children surveyed who within 12–23 months of age had received all childhood immunizations included in the national immunization program.
* Percent of children surveyed who by 18 months of age had received all childhood immunizations included in the national immunization program.
P.M. Luz et al. Vaccine 39 (2021) 125–136Infant vaccination against pertussis was initiated in the 1970s
with notable national increase in coverage after 1973 leading to
a significant reduction in incidence during the 1990s. More
recently, a significant increase in pertussis incidence has been
observed in Brazil with the highest rates in infants younger than
6 months [4] and evidence of pertussis infection among adoles-
cents and adults [26]. Evidence from nationwide studies show an
increase in pertussis incidence as early as 2007 and peaking in
2010–2014 [4,7,27–29]. Some authors have suggested that it could
be associated with decreased vaccination coverage in some parts of
the country and with a switch from DTwPHib to DTwPHib-HBV in
2012 [4,26,28,30]. A more recent study from São Paulo State, in the
Southeast of Brazil, described similar findings with increase in
cases in all age groups in 2011–2014 with a sharp decrease in
2015 [31]. As pointed out by others, the challenges to interpreting
these trends include the recent introduction of new and more sen-
sitive molecular diagnostic methods, including PCR in 2009,
enhanced sensitivity of the surveillance system with selected
hospital-based sentinel sites for severe pertussis surveillance,
enhanced disease awareness as a result of the recent epidemic,
and decrease in infant vaccination coverage over the years
[4,26,28,30,31].
As mentioned in the Introduction, the diphtheria-tetanus vac-
cine was replaced with tetanus-diphtheria-acellular pertussis vac-
cine (Tdap) for pregnant women in 2014 [12]. The rationale for this
strategy is to protect the infant too young to be vaccinated with
transplacental antibody transfer from mother to infant, as well as
to protect the mother and potentially reduce household
transmission.
2.4. Costs
Details of the cost data are provided in the Technical Appendix
(Section #4). Briefly, in the present, we included direct medical
costs pertaining to pertussis disease and the costs of the vaccines.
Costs of pertussis outpatient cases were estimated based on stan-
dardized guidelines for pertussis case management and included
diagnostic exams, medical visits, and medications. Costs of inpa-
tient pertussis cases, stratified by age sub-group and by patient
outcome (survive/death) were derived from reimbursements paid
for all pertussis hospitalizations in 2014 in the hospitals of the
Brazilian National Public Health system (SUS), which covers 75%
of the Brazilian population.
Brazil began maternal aP immunization in 2014 using a single
dose vaccine of multivalent formulation (adolescent/adult TdaP)
purchased through the Pan American Health Organization Revolv-
ing Fund. To the base price per dose (USD 8.9), freight and insur-
ance charges (3%) and a service charge (4.25%) were added,
bringing the total to USD 9.55. An additional 5% wastage rate, as
recommended by WHO and varied between 0 and 15% in sensitiv-
ity analyses, was added (total cost USD 10). Delivery costs were not
separately estimated for maternal aP immunization since Td is128being replaced by TdaP, as such it is assumed that there is no incre-
mental cost of delivering TdaP.
For infant wP vaccines, we used the 2014 listed dose price for
the single dose pentavalent vaccine DTwPHib-HBV liquid formula-
tion, which is purchased through the Pan American Health Organi-
zation Revolving Fund. To the base price per dose, freight and
insurance charges (3%) and a service charge (4.25%) were added,
totaling USD 2.71. An additional 5% wastage rate, as recommended
by WHO and varied between 0 and 15% in sensitivity analyses,
brings the cost for each vaccine dose to USD 2.84. The cost of deliv-
ering a dose of vaccine for any individual was obtained from a pri-
mary study conducted in 2013 in Brazil which estimated the cost
of the immunization program in the country [32].
2.5. Model fitting
An important step towards documenting the credibility and
usefulness of a model is the process of model fitting. This involves
exploring the different model structures as well as different
parameter values which are varied within a priori plausible bounds
to identify combinations that provide a better fit between model
predicted time series and observed data. Parameters whose values
were highly uncertain, even after consulting the available evi-
dence, were derived during model fitting; these included: report-
ing probability for symptomatic cases, a multiplier that scales the
probability of infection per contact, waning of immunity from
infection, and duration of infection.
As calibration targets, we initially used monthly age-specific
observed data from official sources for each Brazilian state for
the period 2000–2016 and subsequently aggregated the data into
one annual time series of cases for each age group (<1, 1–9, and
10+ years of age) to ease computational burden. These calibration
targets were fitted to model predicted age-specific time series of
infections which were grouped into the corresponding age groups:
<1 year, 1–9 years and 10+ years of age, for each Brazilian state
(São Paulo, Paraná, Bahia). Further details on the calibration targets
and model predictions as provided in the Technical Appendix,
Section #6.
To assess goodness of fit, we used graphical displays and multi-
ple goodness-of-fit (GOF) statistics including the mean absolute
error (MAE), which measures the average magnitude of the errors
in a set of predictions; the root mean square error (RMSE), which
gives the standard deviation of the prediction error; the normal-
ized root mean square error (NRMSE), given in percentage; and
the ratio of the RMSE to the standard deviation of the observations
(RSR). For all these measures, the lower the value, the better the fit.
2.6. Interventions, primary outcome and analysis
The strategies modeled were 1) routine childhood pertussis wP
vaccination only and 2) routine childhood wP vaccination plus aP
maternal immunization. The impact of each strategy was simu-
P.M. Luz et al. Vaccine 39 (2021) 125–136lated over a time horizon of 16 years, from 2014 when maternal aP
immunization was introduced in Brazil to the end of 2029. We
assumed the perspective of the Brazilian National Health system
that accounts for direct medical costs for vaccination and disease
treatment. Health, cost and cost-effectiveness outcomes were dis-
counted at 3%, and the costs were expressed in 2014 US dollars.
For the cost-effectiveness analysis, our primary outcome was
cost per disability-adjusted life year (DALY) averted. The number
of DALYs was calculated as the sum of the number of years of life
lost due to premature death and the number of years lost due to
disability in the case of outpatient/inpatient cases using published
methods [33]. These calculations used the disability weights for
pertussis obtained from the Global Burden of Disease study [34]
and average Brazilian life-expectancy, 81.75 years, as recom-
mended in recent Burden of Disease studies from Brazil [35]. Fur-
ther details are given in the Technical Appendix, Section #5.
The incremental cost-effectiveness ratio (ICER) of maternal aP
was calculated by dividing the difference in cost between the
two strategies, in 2014 US dollars, by the difference in DALYs
which yields the cost/DALY. The decision to adopt a new interven-
tion can be evaluated by comparing cost/DALY to estimates of soci-
etal willingness-to-pay for additional health gains. For comparison
with prior studies, we defined an intervention as cost-effective if
its cost/DALY averted is less than the state’s per capita Gross Regio-
nal Product [23].
One-way sensitivity analysis was assessed for a range of param-
eters including vaccine effectiveness, waning of immunity from
infection, childhood vaccines and maternal vaccine, likelihood that
the vaccine will fail, duration of infection, reporting probability for
symptomatic cases, disability weight, discount rate, and costs (out-
patient, inpatient, vaccine administration costs, maternal vaccine
cost). Probabilistic sensitivity analyses were not performed as per
current recommendations for dynamic transmission models [36].3. Results
3.1. Model structure
Figs. 1–3 show, by state, the monthly number of outpatient and
inpatient cases and deaths by aggregated age groups (<1, 1–9, and
10+ years of age). Numbers of outpatient and inpatient cases and
deaths were very low before 2010 and increased sharply between
2010 and 2014, as other epidemiologic studies from several
regions in Brazil have shown [4,29,31]. Inpatient cases exceeded
outpatient cases in those <1 year of age likely due to the higher
probability of severe disease in this age group.
Inspection of the graphical displays (Figs. 4–6) show that mod-
els fitted reasonably well to the observed data though all models
miss the 2014 peak by a substantial amount (Figs. 4–6): the SIR
produced the worst fit and the SIRS and the SIRSIs models fit best
with small improvement in the fit statistics (Table 3). Among
states, we see that the model for Paraná has the lowest NRMSE
meaning that it had the best fit when compared to São Paulo and
Bahia.
Parameter values derived during model fitting included: report-
ing probability for symptomatic cases (São Paulo 3.4%, Paraná 2.5%,
Bahia 1.4%), the multiplier that scales probability of infection
(10, not state-specific), waning of immunity from infection
(25 years, not state-specific) and duration of infection (25 days,
not state-specific).3.2. Cost-effectiveness of aP immunization in the 3 states
The incremental cost-effectiveness of maternal aP immuniza-
tion was USD 3068, 2962 and 2022 per DALY averted in São Paulo,129Paraná and Bahia, respectively (Table 4). The following sections
detail the results for each state and the impact of parameter uncer-
tainty on the results.3.3. São Paulo
Maternal vaccination has an impact on all health outcomes, par-
ticularly deaths. With maternal vaccination, outpatient and inpa-
tient cases decreased to 81,078 and 15,250 (52% of outpatient
and 68% of inpatient cases were averted). Deaths in infants <1 year
of age dropped to 70 and years of life lost due to pertussis dropped
to 5651. Overall, 77% of the DALYs expected to be lost to pertussis
were averted by maternal vaccination. Total costs were higher with
maternal vaccination than for routine infant wP vaccination alone,
with vaccine costs increasing by USD 75 million while medical
costs decreased to 8.3 million. In total, incremental costs of mater-
nal vaccination amounted to USD 57.9 million.
One-way sensitivity analyses showed that, in order, reporting
probability for symptomatic cases, infection duration, aP vaccine
cost and infant wP vaccine coverage were the most influential
parameters. None of these parameters, however, led to cost-
effectiveness ratios that exceeded São Paulo’s gross regional pro-
duct per capita (17,881 USD in 2014).
Reporting probability for symptomatic cases, a highly uncertain
parameter, was varied within the range estimated in the model fit-
ting process. A higher reporting probability (10.4%) implied a much
higher burden of cases and deaths yielding significantly higher
medical costs. In this scenario, aP becomes more cost-effective, at
392 USD/DALY averted. In contrast, when reporting probability
was lower (1.2%), reported cases, deaths, and medical costs
decreased substantially. In this scenario, vaccine costs represent
a higher fraction of total costs and the cost of maternal immuniza-
tion increases to USD 10,731 USD/DALY averted.
The impact of infection duration is similar in that when the
infectious period is longer, more cases/deaths are expected, leading
to a lower cost/DALY averted (when infection lasts 28 days, rather
than 25 as in the base case, USD 2319/DALY). When the infectious
period is shorter (21 days), there are fewer cases/deaths and lower
medical costs, with the result that maternal immunization costs
USD 9823/DALY. At a higher vaccine cost (15 USD) maternal immu-
nization costs USD 4620/DALY (50% higher than base case) while at
lower cost (5 USD) it costs USD 1773/DALY (half of base case).
Increasing infant wP vaccine coverage to levels reported in 1996
in São Paulo, which were higher than those in 2007 makes mater-
nal immunization less attractive (USD 4719/DALY averted). Simi-
larly, when infant vaccination is assumed more effective (for
example, when wP vaccine failure is assumed to be zero), maternal
immunization becomes less attractive (USD 4350/DALY averted).3.4. Paraná
With maternal vaccination, 27% of outpatient and 38% of inpa-
tient cases were averted. Deaths in infants <1 year of age dropped
to 66 and years of life lost due to pertussis dropped by 50%. Overall,
50% of the DALYs expected to be lost to pertussis were averted by
maternal vaccination. Total costs were higher due to vaccine costs.
Paraná’s gross regional product in 2014 was 13,310 USD making
maternal immunization in Paraná a cost-effective strategy, costing
USD 2962 per DALY averted.
The same parameters that were most influential in São Paulo
were also the most influential in Paraná. The reporting probability
for symptomatic cases was the only parameter that led to signifi-
cant changes with maternal immunization becoming more attrac-
tive when reporting probability was higher than base case (7.9%,
USD 621/DALY averted) and not attractive when the reporting
Fig. 1. Age-specific (<1 year, 1–9 years and 10+ years of age) monthly pertussis deaths (solid), inpatient cases (dotted) and outpatient cases (dashed) from Brazilian official
sources in São Paulo, 2000–2016.
P.M. Luz et al. Vaccine 39 (2021) 125–136probability was lower than base case (0.4%, USD 18,604/DALY
averted).
Increasing infant wP vaccine coverage to levels reported in 1996
in Paraná, which were higher than those in 2007 makes maternal
immunization less attractive (USD 11,483/DALY averted). Com-
pared to São Paulo and Bahia, the influence of infant wP vaccine
coverage on the cost-effectiveness ratio was most striking for
Paraná, a state where vaccine coverage has remained high over
the years.3.5. Bahia
Bahia was the state with the lowest estimated vaccination cov-
erage and highest infant case-fatality. Nonetheless the results for
the cost-effectiveness of maternal aP immunization were very sim-
ilar to those in São Paulo and Paraná. In Bahia, the cost/DALY of
maternal aP immunization was estimated at a third of Bahia’s gross
regional product per capita (USD 6273 in 2014).130Again, the reporting probability for symptomatic cases was the
most influential parameter, with maternal immunization costing
USD 15,335/DALY averted when reporting probability was lower
than base case (0.2%) and USD 395/DALY when reporting probabil-
ity was higher than base case (5.2%). One-way sensitivity analyses
again showed that, in order, infection duration, aP vaccine cost and
wP vaccine coverage were also influential parameters though not
to the point of making maternal vaccination not cost-effective.
4. Discussion
We developed and tested three dynamic transmission model
structures (SIR, SIRS, SIRSI) parameterized to represent three dis-
tinct lower-middle and upper-middle income settings and used
the best fitting model structure to project the cost-effectiveness
of maternal aP immunization. We found that the same model
structure fit all three settings, despite their different demographic
and socio-economic conditions. The SIR model structure showed
the poorest fit to the data suggesting that to adequately capture
Fig. 2. Age-specific (<1 year, 1–9 years and 10+ years of age) monthly pertussis deaths (solid), inpatient cases (dotted) and outpatient cases (dashed) from Brazilian official
sources in Paraná, 2000–2016.
P.M. Luz et al. Vaccine 39 (2021) 125–136pertussis dynamics it is important to allow for waning immunity
and repeat infections, as previous studies have suggested [14].
The difference in fit between the twomodels that incorporate wan-
ing (SIRS and SIRSIs) was minimal. That the same model structure
provides the best fit to all three states best supports the idea that
the disease behaves similarly across different socioeconomic con-
ditions and that it may apply to other lower- and middle-income
settings. Thus this analysis provides support for our use of an SIR-
SIs model fitted to Brazilian disease data, with appropriate changes
in key parameter values, to evaluate the cost-effectiveness of
maternal immunization [37].
In dynamic models, the rate at which susceptible individuals
become infected depends on the number of infectious individuals
in the population at any given time [38]. This force of infection is
crucial to the evaluation of vaccine programs because vaccination
not only reduces the incidence of disease in those immunized, by
direct protection, but also indirectly protects nonvaccinated indi-
viduals against infection [38]. This indirect protection is often
referred to as herd immunity [39–41]. In the simplest case, disease131incidence should be reduced by a factor that is proportional to the
product of vaccine coverage and vaccine efficacy [40]. However, a
more realistic analysis, as Fine and colleagues suggests, should
consider ‘‘(1) the distribution of vaccines and of disease risk in
communities; (2) the nature of the immunity induced by the vac-
cine; as well as (3) the indirect protection of nonimmune persons
by the presence of immune persons” [40]. Consideration of these
factors implies that pertussis dynamics varies significantly over
time and space.
Our models were developed following current recommenda-
tions for model conceptualization and validation. Recent literature
has recommended that models aiming to assess the effect of vacci-
nation should not apply the simulated vaccine program at birth nor
at the end of the ‘‘vaccine schedule” (such as the end of the primary
course) [14]. Accordingly, we have modeled vaccination by dose
and age, incorporating both doses given at the recommended ages
and those given later. This approach allowed for greater granularity
in modeling vaccine coverage rates. Moreover, authors have sug-
gested that models that fail to include fluctuations in vaccine cov-
Fig. 3. Age-specific (<1 year, 1–9 years and 10+ years of age) monthly pertussis deaths (solid), inpatient cases (dotted) and outpatient cases (dashed) from Brazilian official
sources in Bahia, 2000–2016.
P.M. Luz et al. Vaccine 39 (2021) 125–136erage over time may not capture cohort effects, particularly when
natural infection leads to long lasting immunity [14]. Our approach
was to assume vaccine coverage changed over time as reported in
nationally representative surveys of vaccine coverage in addition
to published literature [24,25,42–44]. As for more generic charac-
teristics, as suggested [14,45], our models incorporate multiple
age groups, assume age-specific contact rates, and use multiple
sources of local data for parametrization and model fitting.
In agreement with other modeling and economic studies of per-
tussis resurgence and alternative vaccination strategies [14,46], we
found the reporting probability to be the most influential parame-
ter. An analysis from the United States found that differences in the
reporting probability (or reporting rate as it is usually denomi-
nated) implied a change in the decision whether or not to adopt
maternal vaccination [8]. In a study from Australia, the reporting
rate was the second most important parameter influencing the
cost-effectiveness of maternal immunization [47]. When authors
assumed that a higher fraction of cases was reported, maternal
aP was more cost-effective. The reporting rate represents the frac-132tion of infections that require medical attention and thus incur
costs. There are many layers involved in the relationship between
an infection and a reported case including probability of develop-
ing of symptoms, probability of seeking care, physician awareness
and willingness to notify, testing likelihood and accuracy of the
methodology, and notification infrastructure. As a result, one
should use local data to estimate this parameter and/or explore
its impact in sensitivity analysis as reporting rates from a particu-
lar study or population are not applicable to other settings [14].
For the three different settings here explored, we used model
fitting processes to estimate the reporting probability for symp-
tomatic cases that best fitted the observed data. Our estimates
indicated that the reporting probability varied by state, lowest in
Bahia and highest in São Paulo, which might reflect the fact that
São Paulo was one of the first states to institute molecular diagnos-
tic methods and, in general, has more referral centers and
resources [31]. With the estimated reporting probabilities, mater-
nal aP immunization was found to be a cost-effective strategy. A
higher reporting probability than assumed in base case makes
Fig. 4. Comparison between the observed data (circles) and model projected outcomes by model structure SIR (solid), SIRS (dotted) and SIRSIs (dashed) in São Paulo, 2000–
2016.
Fig. 5. Comparison between the observed data (circles) and model projected outcomes by model structure SIR (solid), SIRS (dotted) and SIRSIs (dashed) in Paraná, 2000–2016.
P.M. Luz et al. Vaccine 39 (2021) 125–136maternal aP immunization more cost-effective because the added
costs of the vaccine are offset by the savings in treatment costs.
In contrast, a lower reporting probability compared to base case
leads to maternal aP immunization being less attractive. Epidemi-
ologic studies of pertussis disease burden suggest that cases are
significantly underreported even in high-income settings [48–51]
and thus that lower estimates for the reporting probability are
more realistic.
We also found that higher infant wP vaccine coverage made
maternal aP immunization a less attractive strategy. The reasoning
for this finding is that as fewer notified cases occur, due to high
infant vaccine coverage, there is less disease burden to be averted
by maternal immunization. However, current infant wP vaccine
coverage levels have not significantly decreased transmission,
leading to an increased disease burden in recent years, in particular
among infants <1 year who are most likely to be symptomatic,
require hospitalization, and die [4,31,32]. Given currently observed133pertussis incidence and infant coverage, maternal aP immunization
would be a cost-effective strategy if the cost-effectiveness bench-
mark is each state’s GDP per capita, or even half of GDP per capita.
Our results and conclusions are similar to those for Brazil as a
whole [37]. Specifically, if infant wP vaccine coverage remains
low, maternal aP immunization is cost-effective. At higher infant
vaccine coverage rates (such as reported in 1996) the cost/DALY
averted of maternal aP immunization is higher as there is less dis-
ease to be averted. In our analysis, the impact of higher infant vac-
cine coverage was most striking for Paraná, the state with highest
coverage [24]. These findings evidence the contribution of herd
immunity to the non-linear behavior of the dynamic model system
[39].
Relatedly, in an accompanying paper [52], we compare mater-
nal aP immunization cost-effectiveness results using a dynamic
and a static model and highlight when the static model is likely
sufficient for informing public health decisions. Results show that
Fig. 6. Comparison between the observed data (circles) and model projected outcomes by model structure SIR (solid), SIRS (dotted) and SIRSIs (dashed) in Bahia, 2000–2016.
Table 3
Model goodness-of-fit statistics by model type and state: mean absolute error (MAE),
root mean square error (RMSE), normalized root mean square error (NRMSE), and the
ratio of the RMSE between the predictions and actual observation to the standard
deviation of the observations (RSR).
MAE RMSE NRMSE (%) RSR
São Paulo
SIR 141.7 239.5 65.4 0.65
SIRS 129.9 221.6 60.5 0.60
SIRSIs 121.5 221.5 57.8 0.58
Paraná
SIR 20.5 35.9 45.3 0.45
SIRS 20.6 33.6 42.4 0.42
SIRSIs 19.8 32.3 40.7 0.41
Bahia
SIR 25.2 47.9 61.5 0.62
SIRS 22.6 44.2 56.8 0.57
SIRSIs 21.0 42.3 54.3 0.54
P.M. Luz et al. Vaccine 39 (2021) 125–136if infant vaccine coverage is low, then maternal immunization is
cost-effective irrespective of model type. In contrast, when infant
vaccine coverage is extremely high, then the dynamic transmission
model is capable of showing how maternal immunization might
not be cost-effective while the static model continues to suggest
the strategy would be cost-effective. The rationale for implement-
ing maternal aP immunization is direct protection of the newborns
(0–2 months) through the maternal antibodies. As such, one could
argue that having a maternal aP immunization in addition to infant
vaccination could be valuable in settings where infant vaccine cov-
erage cannot be expected to be maintained at a consistently high
level over space and time. That is, if infant vaccine coverage is
expected to vary, then maternal immunization acts as a backup,
for safety, preventing infection among those who are most vulner-
able to severe disease and death. For the present analysis, we
reviewed available data on infant vaccine coverage for Brazil and
its states and municipalities and found significant heterogeneity
in space and time [24,25,43,44], a scenario likely experienced in
other low and middle income countries [53,54].
We note a few important considerations on the concept of a
‘‘threshold proportion of immune persons that, if reached, could
eliminate infection” (for a more complete assessment please refer
to [40]). The herd immunity threshold is ‘‘an epidemiologic attri-
bute with which to characterize particular infections” for which
rough estimates have been generated [40]. In reality, however,134heterogeneities in population demography, social structure, and
contact rates (within and between age groups), the degree and
duration of immunity elicited by pathogen and vaccine, as well
as the stochastic nature of epidemic processes play a role in deter-
mining the level of vaccination required to eliminate disease in a
particular time and place [40]. Though our levels of vaccine cover-
age were relatively high, for Paraná in particular, results show that
it is likely far from decreasing incidence to the point of elimination.
Moreover, studies have shown a significant reduction in vaccine
coverage, to levels clearly below any threshold, at the municipal
level (83% of Brazilian municipalities reporting DTP coverage of
95% in 2006 but only 55% in 2012) [29]. Incomplete vaccine cover-
age has been suggested as the reason for pertussis resurgence in
Massachusetts as well [55].
Our study has several strengths and limitations that should be
acknowledged. One strength was the use of local data to inform
model fitting and parameter values. However, as observed in other
settings [48–50], notified pertussis cases represent only a fraction
of disease incidence which has influenced our fitting of the report-
ing probability parameter. In particular with regards to the 2014
increase in the number of reported cases, uncertainty about
parameter values and model structure are among possible expla-
nations for the under-fitting of the observed data. Of note is that,
overall, all models under-fit the observed data for the age group
<1 year meaning that maternal aP immunization cost-
effectiveness ratios may well represent conservative estimates.
Perhaps other modeling strategies, such as stochastic or
individual-based models, could better address the weakness of
the current work though these would add their own challenges
such as high dimension of the parameter space, program coding
complexity, increased computer processing time, and subsequent
parameter non-identifiability. A limitation is that vaccine coverage
rates used to inform the model were available for only a few time
points and that heterogeneities in coverage [24,44] were neglected.
Moreover, for some parameters, such as the contact matrix, we had
no local or Brazilian data and thus had to use data from countries
with similar characteristics. The computational burden of fitting
three different models to scarce observed data also limited the
range of uncertainties that could be explored in sensitivity analy-
ses. One example pertains to the reporting probability which was
not age-specific and, for the SIRSI model that requires a reporting
probability for secondary infections, an a priori assumption was
Table 4
Impact of maternal aP on outpatient and inpatient cases, deaths, years of life lost, disability adjusted life-years and costs in São Paulo, Paraná, and Bahia, 2014–2029.
São Paulo Paraná Bahia
No aP With aP No aP With aP No aP With aP
Outpatient cases
<1 year 15,237 3,547 3,756 1,877 2,902 1,242
1–9 years 46,957 25,066 9,702 7,877 7,014 5,540
10+ years 106,626 52,466 20,816 15,316 14,473 10,182
Total 168,820 81,078 34,273 25,069 24,389 16,966
Outpatient cases averted (N) 87,742 9,204 7,423
Outpatient cases averted (%) 52.0 26.9 30.4
Inpatient cases
<1 year 22,856 5319 5629 2814 4359 1865
1–9 years 22,088 8810 5507 4043 3944 2707
10+ years 2452 1125 489 351 339 229
Total 47,399 15,250 11,626 7208 8643 4802
Inpatient cases averted (N) 32,148 4418 3841
Inpatient cases averted (%) 67.8 38.0 44
Deaths 301 70 138 66 201 85
Deaths averted (N) 232 72 116
Years of life lost (YLL) 24,288 5651 10,861 5,428 16,391 7011
YLL averted (N) 18,637 5433 9380
YLL averted (%) 76.7 50.0 57.2
DALYs
<1 year 24,363 5668 10,881 5,439 16,405 7,017
1–9 years 138 66 25 25 25 13
10+ years 213 104 38 26 25 22
Total 24,712 5840 10,950 5493 16,453 7055
DALYs averted (N) 18,872 5458 9399
DALYs averted (%) 76.4 49.8 57.1
Costs (USD millions)
Medical treatment 25.7 8.3 6.3 3.8 4.7 2.6
Vaccine 164.5 239.8 66.6 85.2 40.4 61.5
Total 190.3 248.2 72.9 89.0 45.1 64.1
Incremental costs 57.9 16.2 19.0
Cost (2014 USD) per DALY averted 3068 2962 2022
P.M. Luz et al. Vaccine 39 (2021) 125–136made that its value be one-tenth of the reporting probability for
primary infections. These assumptions, in turn, led to an age-
dependent reporting probability effect in the SRISI model as it con-
siders secondary infections that occur later in life. In addition,
some aspects of pertussis natural history and the impact of vacci-
nes, such as boosting or blunting of immunity from maternal anti-
bodies, were not considered. Importantly, and following the
recommendations highlighted in three reviews of economic analy-
ses of pertussis vaccination strategies [46,56,57], limited under-
standing of important aspects of pertussis epidemiology suggests
caution when extrapolating our results. More studies are needed
to better inform the relationship between infection and case noti-
fication, the duration of immunity conferred by infection and vac-
cines, and how boosting of immunity may result from silent
infections. Finally, though we did explore different model struc-
tures, we relied on an objective comparison of the goodness of fit
of the three models, choosing the one with the best fit. The chosen
model (SIRSIs) however, is less parsimonious than the SIRS model.
Nonetheless, dynamic transmission models are useful for pro-
jecting potential health outcomes and generating evidence for pol-
icy recommendations. We have shown that the SIRSIs model
structure fit best the pertussis epidemiology of three settings that
represent diverse socio-demographic conditions. It is thus reason-
able to suggest that the same structure can represent disease
transmission in a range of lower- and middle-income settings
[37]. Our results also highlight the implications of the under-
reporting of diseases which may lead to an underestimation of
the value of reducing disease burden.Authors contributions
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